Offering support to those impacted in Turkey & Syria
We are deeply saddened by the tragic earthquake across Turkey and Syria and the worsening humanitarian crisis. Our thoughts are with all of those impacted by the devastating events and our gratitude to those who are bravely leading the rescue efforts.
As part of our commitment to ensuring patients have access to treatments, Ipsen will be donating financial and medical aid to the value of €100K to help those in need. We are collaborating with Association Tulipe, a humanitarian distribution establishment which federates donations from health companies to populations in distress. We are also working closely with a local distributor to deliver donations of critical medicines to care providers delivering aid across the regions.
We will continue to closely follow the situation and stand in solidarity with those affected.
Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
Ipsen to present data across five rare liver diseases at AASLD 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
Ipsen announces sale of Priority Review Voucher for $158m
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation
Ipsen and Medetia join forces to accelerate early research in rare disease